Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Non-cash Items (2019 - 2025)

Historic Non-cash Items for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $6.0 million.

  • 4D Molecular Therapeutics' Non-cash Items rose 4539.81% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year increase of 4539.81%. This contributed to the annual value of $4.5 million for FY2024, which is 9031.25% down from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Non-cash Items of $6.0 million as of Q3 2025, which was up 4539.81% from $5.5 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' Non-cash Items' 5-year high stood at $48.0 million during Q4 2022, with a 5-year trough of $1.4 million in Q2 2021.
  • Its 5-year average for Non-cash Items is $9.0 million, with a median of $3.3 million in 2024.
  • In the last 5 years, 4D Molecular Therapeutics' Non-cash Items surged by 9480.26% in 2022 and then crashed by 9031.25% in 2024.
  • Quarter analysis of 5 years shows 4D Molecular Therapeutics' Non-cash Items stood at $24.7 million in 2021, then skyrocketed by 94.8% to $48.0 million in 2022, then dropped by 2.47% to $46.9 million in 2023, then plummeted by 90.31% to $4.5 million in 2024, then surged by 32.49% to $6.0 million in 2025.
  • Its Non-cash Items stands at $6.0 million for Q3 2025, versus $5.5 million for Q2 2025 and $5.0 million for Q1 2025.